As a part of the Viatris deal, Biocon Biologics has acquired Viatris’ rights to its biosimilar Aflibercept asset, (partnered with Momenta), a proposed biosimilar to Regeneron’s Eylea, which is indicated for use in multiple ophthalmological indications. Viatris has been the ‘first to file’ for a biosimilar Aflibercept in the U.S.

Aflibercept*

Filed: Filed for approval in the U.S., EU, UK and Japan